Etoposide-related acute promyelocytic leukemia

Leukemia. 1998 Aug;12(8):1171-5. doi: 10.1038/sj.leu.2401089.

Abstract

The development of therapy-related acute myeloid leukemia (t-AML) has become a growing concern over the past decade, because of the increase in the percentage of long-term survivors of primary malignancy. We reviewed 17 cases with etoposide-related acute promyelocytic leukemia (APL) reported in the literature. The close association between treatment with etoposide for Langerhans cell histiocytosis (LCH) and the development of etoposide-related APL was demonstrated among Japanese and Italians. Our data on the breakpoints (b/ps) of the PML and RARalpha genes are presented. It is suggested that chromatin structure might be more important than specific consensus sequence in the distribution of b/ps in etoposide-related APL.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Phytogenic / adverse effects*
  • Base Sequence
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 15
  • Chromosomes, Human, Pair 17
  • Etoposide / adverse effects*
  • Female
  • Humans
  • Infant
  • Leukemia, Promyelocytic, Acute / etiology*
  • Leukemia, Promyelocytic, Acute / genetics
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Neoplasm Proteins / genetics*
  • Neoplasms, Second Primary* / genetics
  • Oncogene Proteins, Fusion / genetics*
  • Topoisomerase II Inhibitors

Substances

  • Antineoplastic Agents, Phytogenic
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • Topoisomerase II Inhibitors
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • Etoposide